The original success of Sildenafil undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on generic versions presents a challenging picture. Although early earnings were substantial, the cessation of patents and the rise of less expensive alternatives have diminished the customer base. Consequently, a thorough eval